Pregnancy Due Date Calculator: Naegele’s Rule, Conception Date, and Ultrasound Dating Methods with Trimester Calendar and Prenatal Milestone Timeline

The accuracy of an LMP-based due date depends primarily on the regularity of the menstrual cycle and the certainty of the LMP date. For women with regular 28-day cycles who are certain of their LMP date, the LMP method produces a due date that corresponds to actual delivery within about 2 weeks (in either direction) for approximately 90% of women. Research on US birth data shows that the median error of LMP-based dating is approximately 7 to 10 days. The main sources of inaccuracy are: irregular cycle length (if ovulation occurs earlier or later than day 14 of the cycle, the conception date and thus the due date shifts accordingly); uncertain LMP recall (studies show that a meaningful percentage of women are uncertain of their LMP date within a range of several days to a week); bleeding in early pregnancy that may be mistaken for a menstrual period; and individual variation in implantation timing. First trimester ultrasound dating (CRL measurement between 8 and 13 weeks) is considered more accurate than LMP dating, with an error range of plus or minus 5 to 7 days versus 7 to 14 days for LMP. The ACOG Committee Opinion 700 (available at acog.org) provides the authoritative US guidance on methods of gestational age estimation and criteria for reating a pregnancy based on ultrasound findings that differ from LMP-derived dates. For clinical management decisions (preterm birth evaluation, post-dates management), the sonographic EDD from the first trimester ultrasound takes precedence over LMP dating when a discrepancy exists.

The three trimesters are defined differently in different sources, which can create confusion. The most commonly used clinical definition in US obstetrics, based on ACOG guidelines, is: First trimester from week 1 through the end of week 13 (counting from LMP, so conception to about 11 weeks of fetal development); second trimester from week 14 through the end of week 27 (approximately 4 to 6 months); third trimester from week 28 through the end of week 40 at the due date. Alternative definitions sometimes used are: first trimester through week 12 (rather than 13), second trimester from week 13 through 26, and third trimester from week 27. This calculator uses the ACOG-aligned definition of trimester 1 ending at week 13 and trimester 3 beginning at week 28. In practice, many OB-GYNs and popular pregnancy resources use slightly varying cutpoints, so you may see trimesters described as ending at 12, 13, or 14 weeks for the first trimester depending on the source. The practical clinical significance is greatest at the beginning of the third trimester, which is when preterm birth monitoring intensifies and fetal lung development becomes a primary concern (corticosteroid administration to accelerate lung maturity is indicated for preterm labor before 34 weeks). The end of the second trimester also coincides roughly with the gestational age of viability (24 weeks), making the transition from second to third trimester clinically significant for premature birth management.

ACOG formally defined terminology for pregnancy term status in a 2013 document (available at acog.org) that replaced the previous “preterm/term/post-term” binary with a five-category system reflecting the full spectrum of gestational age at birth. Pre-term pregnancy is any birth before 37 weeks 0 days, subdivided into late preterm (34-36 weeks 6 days), moderately preterm (32-33 weeks), very preterm (28-31 weeks), and extremely preterm (before 28 weeks). Early term is 37 weeks 0 days through 38 weeks 6 days. Full term is 39 weeks 0 days through 40 weeks 6 days. Late term is 41 weeks 0 days through 41 weeks 6 days. Post-term is 42 weeks 0 days and beyond. This terminology matters clinically because early term births (37-38 weeks), while commonly considered “term” in lay language, are associated with higher rates of respiratory complications, NICU admission, feeding difficulties, and longer hospital stays compared to births at 39-40 weeks. The safest gestational age for elective delivery (when no medical indication exists for early delivery) is 39-40 weeks, which is why ACOG and the CDC discourage elective inductions before 39 weeks in low-risk pregnancies. This calculator marks both 38 weeks (early term) and 39 weeks (full term) in the milestone calendar so you can clearly see when these clinically significant thresholds arrive relative to your estimated due date.

US prenatal care guidelines recommend starting prenatal vitamins ideally before conception or as soon as pregnancy is confirmed, because folic acid (critical for neural tube formation) must be adequate in the first 4 to 8 weeks of pregnancy, often before the pregnancy is known. The key nutrients in US prenatal vitamins and their recommended amounts during pregnancy are: folic acid (600 micrograms per day from food and supplements combined, with 400-800 mcg in the supplement itself, per CDC recommendations at cdc.gov/folicacid); iron (27 mg per day during pregnancy, up from 18 mg non-pregnant daily value); calcium (1000 mg per day for adults 19-50); vitamin D (600 IU per day, though many OB-GYNs recommend 1000-2000 IU); iodine (220 mcg per day, critical for fetal brain development); and DHA (docosahexaenoic acid, an omega-3 fatty acid, 200 mg per day recommended by ACOG for brain and eye development). The FDA and USDA dietary guidelines at choosemyplate.gov/life-stages/pregnancy provide additional nutritional guidance for pregnant US women. Prenatal vitamins are considered over-the-counter in the US and do not require a prescription, though prescription prenatal vitamins are available through insurance, often with higher iron and DHA content or in different formulations for women with nausea. Women who are vegan or vegetarian should discuss vitamin B12 supplementation with their OB-GYN, as this nutrient is essential for fetal neurological development and is found primarily in animal products.

The anatomy ultrasound (also called the level II ultrasound, mid-pregnancy ultrasound, or 20-week scan) is typically performed between 18 and 22 weeks of pregnancy and is the most comprehensive prenatal imaging study done during routine pregnancy care. A trained sonographer or maternal-fetal medicine specialist systematically examines and measures all major fetal anatomical structures, including the brain (cerebellum, ventricles, corpus callosum), face and facial features, spine integrity (to detect spina bifida), heart (four chambers, great vessels, valve function), lungs, diaphragm, abdominal organs (stomach, kidneys, bladder), limbs and extremities (femur length, humerus length), abdominal wall (to detect gastroschisis or omphalocele), and umbilical cord insertion. Beyond fetal anatomy, the scan evaluates placental location (to detect or rule out placenta previa, where the placenta covers the cervix), amniotic fluid volume (oligohydramnios or polyhydramnios indicating potential problems), cervical length (short cervix increases preterm birth risk), and fetal position and biometric measurements to confirm appropriate growth. Sex determination is offered (and usually accepted) at this scan in US practice, though parents who prefer to be surprised can request the sonographer not to disclose the sex. The anatomy ultrasound is covered by most US health insurance under the ACA as standard prenatal care. Results are typically reviewed by your OB-GYN at a follow-up appointment, and any concerning findings may prompt referral to a maternal-fetal medicine (MFM) specialist for further evaluation. ACOG’s patient education resources at acog.org provide detailed information on what the anatomy ultrasound evaluates and what to expect from the appointment.

Gestational diabetes mellitus (GDM) is diabetes that develops during pregnancy in women who did not have diabetes before becoming pregnant. It occurs when pregnancy hormones (particularly human placental lactogen and progesterone) cause insulin resistance in maternal cells, and the pancreas cannot produce enough additional insulin to maintain normal blood glucose levels. GDM affects approximately 6-9% of US pregnancies per the CDC, with higher rates in women who are overweight or obese, have a family history of type 2 diabetes, are over 35, or belong to certain ethnic groups (Hispanic, Asian American, African American, and Native American women have higher GDM rates). The standard US screening protocol is the 1-hour glucose challenge test (GCT) between 24 and 28 weeks: the patient drinks a 50-gram glucose solution and has blood drawn exactly 1 hour later without fasting beforehand. A result above the threshold (typically 130 to 140 mg/dL, which varies by practice) triggers the 3-hour oral glucose tolerance test (OGTT), the definitive diagnostic test: the patient fasts overnight, has a fasting blood draw, drinks a 100-gram glucose solution, and has blood drawn at 1, 2, and 3 hours. A diagnosis of GDM requires two or more abnormal values on the 3-hour OGTT. Women at high risk for GDM (previous GDM, BMI above 35, prior macrosomic baby) may be screened at the first prenatal visit in addition to the 24-28 week screen. Gestational diabetes is managed through dietary modification, blood glucose monitoring, and insulin or medication if needed, and resolves for most women after delivery. The CDC’s gestational diabetes resources at cdc.gov and ACOG’s GDM guidelines at acog.org provide detailed information on diagnosis, treatment, and postpartum management.

Group B Streptococcus (GBS, or Streptococcus agalactiae) is a bacterium that normally lives in the gastrointestinal and genital tracts of approximately 10-30% of healthy adults without causing symptoms or illness. In pregnant women who are GBS carriers, the bacteria can be transmitted to the baby during labor and delivery (via contact with the birth canal or amniotic fluid), and in newborns, GBS can cause early-onset GBS disease, a potentially serious and rapidly progressive infection including sepsis, pneumonia, and meningitis. Early-onset GBS disease occurs in approximately 0.5 per 1000 live births in the US per CDC data, a rate that has been reduced dramatically (from approximately 1.5 per 1000 in the early 1990s) through universal GBS screening and prophylactic antibiotic treatment of GBS-positive women during labor. The GBS screening test is a simple vaginal-rectal swab culture performed between 36 and 37 weeks of pregnancy. The timing of 36-37 weeks is chosen because GBS colonization status can change during pregnancy (a woman who tests negative earlier may be positive at delivery), and the test performed within 5 weeks of delivery reliably predicts colonization status at the time of labor. Women who test positive receive IV penicillin (or another antibiotic if penicillin-allergic) during active labor, which is highly effective at preventing GBS transmission to the newborn. The CDC’s GBS prevention guidelines at cdc.gov and ACOG’s GBS clinical practice guidelines provide the evidence base for universal screening and intrapartum prophylaxis as the standard of care in all US hospitals.

It is common for a due date to be adjusted (redated) after an ultrasound, particularly after a first trimester ultrasound that provides a more accurate gestational age estimate than the LMP method alone. Per ACOG guidelines, the threshold for redating (adjusting the official EDD based on ultrasound findings) depends on when the ultrasound was performed: in the first trimester (up to 13 weeks 6 days), redate if the ultrasound EDD differs by more than 7 days from the LMP EDD; in the second trimester (14 weeks through 27 weeks 6 days), redate if the difference is more than 10 days; in the third trimester (28 weeks onward), redate only if the difference exceeds 21 days. These thresholds reflect the increasing variability in fetal measurements at later gestational ages (third trimester ultrasound biometric measurements can vary by several weeks due to individual fetal growth variation). When a due date is changed, all the milestone dates on your prenatal calendar shift accordingly, which is why the ultrasound dating option in this calculator generates a complete new milestone calendar from the updated EDD. A due date change of 7 to 10 days is not cause for concern; it simply means the ultrasound measurements are providing a more accurate estimate than the LMP method allowed. The ACOG’s patient education materials at acog.org explain the process of gestational age estimation and when redating is clinically appropriate in accessible language for expectant parents.

Prenatal genetic screening and diagnostic testing options in the US have expanded significantly in the last decade, and ACOG recommends that all pregnant women be offered information about both screening and diagnostic options regardless of age, with the decision to test left to the patient after informed counseling. The main options available are: Cell-free fetal DNA (cfDNA) testing, also called noninvasive prenatal testing (NIPT) or noninvasive prenatal screening (NIPS), performed from 10 weeks onward via a maternal blood draw; it analyzes fetal DNA fragments circulating in maternal blood and screens for trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), and sex chromosome abnormalities with sensitivity above 99% for trisomy 21, making it the most sensitive available screening test. First trimester combined screening, a combination of nuchal translucency ultrasound measurement (10-13 weeks) plus two bloodwork markers (PAPP-A and free beta-hCG), which has a detection rate of 82-87% for trisomy 21. Second trimester quad screen (AFP, hCG, estriol, inhibin A), performed between 15 and 20 weeks, with detection rates around 80% for trisomy 21 and used primarily when first trimester screening was not performed. For diagnostic (as opposed to screening) testing, chorionic villus sampling (CVS) at 10-13 weeks and amniocentesis at 15-20 weeks provide definitive chromosomal diagnosis with greater than 99% accuracy; both are invasive procedures with a small procedural pregnancy loss risk (approximately 0.5-1%). ACOG and the Society for Maternal-Fetal Medicine (SMFM) publications on prenatal genetic testing at acog.org provide the current evidence-based recommendations that guide US clinical practice.

The Family and Medical Leave Act (FMLA) is the primary federal law governing maternity (and paternity) leave in the United States, providing eligible employees with up to 12 weeks of unpaid, job-protected leave per year for the birth and care of a newborn, adoption or foster placement, or a serious health condition including pregnancy-related conditions. FMLA applies to employers with 50 or more employees and to employees who have worked for that employer for at least 12 months and at least 1,250 hours during the past 12 months. Key points about FMLA for expectant parents: the 12 weeks can be used before birth for pregnancy-related medical appointments or complications (prenatal disability leave), for the delivery and hospitalization, and for postpartum recovery and newborn care; FMLA leave can be taken intermittently or on a reduced schedule by agreement with the employer; both parents are eligible for FMLA leave after the birth of a child; FMLA leave is unpaid unless the employer has a paid leave policy or the employee chooses to substitute accrued paid leave. An increasing number of US states and cities have enacted paid family leave programs that supplement FMLA with partial wage replacement during leave, including California, New York, New Jersey, Massachusetts, Connecticut, Washington State, and Oregon among others. The US Department of Labor administers FMLA and provides comprehensive guidance on employee rights and employer obligations at dol.gov/agencies/whd/fmla. Many employers also offer additional maternity/paternity leave beyond FMLA minimums as part of their benefits packages, which has become increasingly common among large US employers in the technology, finance, and healthcare sectors. Expectant parents should notify HR of their pregnancy and planned leave timing early in the second trimester to allow adequate planning for coverage and to understand the full scope of available leave benefits.

This pregnancy due date calculator uses the three standard obstetric dating methods (LMP, conception date, ultrasound) and is designed for pregnancies conceived naturally or through intrauterine insemination (IUI). IVF due date calculators are specifically designed for pregnancies resulting from in vitro fertilization, where the precise date of egg retrieval, fertilization, and embryo transfer is known, allowing more accurate due date calculation than any of the standard methods. The key difference in IVF dating: for a Day 5 embryo transfer (blastocyst transfer, the most common type in modern IVF), the due date is calculated as transfer date plus 261 days; for a Day 3 embryo transfer, the due date is transfer date plus 263 days. These calculations are more precise than LMP dating because the exact day of fertilization and developmental stage at transfer are known with certainty, rather than being estimated from the last menstrual period. Additionally, IVF pregnancies are monitored more intensively in the early weeks by the reproductive endocrinologist, with serial ultrasounds confirming gestational age and development before transfer to standard OB care typically at 8-10 weeks. If you conceived through IVF, use the IVF Due Date Calculator available in the USCalculators.com Health Hub for the most accurate estimated due date based on your specific embryo transfer day and date. For IUI or naturally conceived pregnancies where LMP or conception date is known, this calculator provides the appropriate calculation methodology.

This calculator uses the same Naegele’s Rule and ultrasound back-calculation methods used by US OB-GYN practices, so the results should agree with your provider’s estimated due date when the same input data is used. Any discrepancy between this calculator’s result and your OB-GYN’s official EDD likely reflects either ultrasound redating (your provider used the ultrasound date to adjust the LMP-based estimate), a different LMP date entered (verify you are using the first day of your last normal period), or rounding differences in week and day calculations. The official EDD recorded on your prenatal chart by your OB-GYN is the date that should be used for clinical decision-making, including evaluating preterm labor, planning induction discussions, and scheduling follow-up appointments. This calculator is best used as a personal reference tool for tracking your pregnancy milestones, understanding the timeline of prenatal appointments, calculating how many weeks pregnant you are on any given day, and generating a shareable due date announcement for family or friends. The milestone calendar in the results (prenatal appointments, screening windows, trimester transitions) is based on ACOG-aligned week recommendations and provides general guidance on when to expect various prenatal appointments, though the specific timing of individual tests may vary by provider, health system, and individual pregnancy risk factors. Always follow your OB-GYN’s personalized recommendations, which take into account your specific medical history, risk factors, and insurance coverage, over the general week-based guidance in any online calculator. ACOG’s patient-facing pregnancy resources at acog.org/womens-health provide additional information on what to expect at each prenatal appointment.

The average length of human pregnancy, measured from the last menstrual period (gestational age) in singleton pregnancies is approximately 280 days or 40 weeks, which is the basis for Naegele’s Rule and this calculator. However, this average conceals meaningful individual variation: research on the timing of natural labor in full-term pregnancies shows a standard deviation of approximately 8 to 14 days around the mean, meaning that the range from 38 to 42 weeks encompasses approximately 95% of all spontaneous deliveries in term singleton pregnancies. First pregnancies tend to last slightly longer on average (approximately 41 weeks 1 day for primiparous women, compared to 40 weeks 3 days for multiparous women in a 2013 study by Jukic et al. in Human Reproduction), consistent with the clinical observation that first-time mothers are more likely to go past their due date than women who have had previous deliveries. Research also shows that the calculated due date, while based on an average, has a bimodal distribution of births around it, with a slight peak just before and another just after the EDD rather than a symmetric bell curve centered exactly on day 280. In current US obstetric practice, the standard of care is to offer or recommend induction of labor at 41 weeks 0 days based on the ARRIVE trial results (published in NEJM 2018) showing lower cesarean section rates and no worse outcomes with induction at 39 weeks compared to expectant management, and to strongly recommend induction at 42 weeks when labor has not begun spontaneously, due to increasing risks of stillbirth and placental insufficiency beyond 42 weeks. US vital statistics data on birth timing from the CDC National Center for Health Statistics (available at cdc.gov/nchs) provides population-level data on gestational age at delivery and preterm birth rates across the US.

The APGAR score is a quick assessment of a newborn’s health performed at 1 minute and 5 minutes after birth, developed by anesthesiologist Virginia Apgar in 1952 and still universally used in US hospitals and delivery rooms. It evaluates five criteria: Appearance (skin color), Pulse (heart rate), Grimace (reflex irritability), Activity (muscle tone), and Respiration, each scored 0, 1, or 2 for a maximum possible score of 10. A score of 7 to 10 is considered normal and indicates a healthy newborn who requires only routine post-delivery care. A score of 4 to 6 is moderately low and may indicate the baby needs some medical assistance, such as supplemental oxygen or stimulation. A score of 3 or below is critically low and requires immediate medical intervention, including possible resuscitation. The 1-minute APGAR score indicates how well the baby tolerated the labor and delivery process; the 5-minute score reflects how well the baby is adapting to the external environment. APGAR scores are not predictive of long-term health outcomes for the vast majority of newborns: many healthy babies have lower scores at 1 minute due to normal transition physiology and then quickly improve to normal scores at 5 minutes. The score is part of standard newborn documentation in all US hospitals and is typically not communicated to parents until the pediatric assessment is complete. Detailed information on newborn assessment procedures is available through the American Academy of Pediatrics at aap.org.

The following symptoms during pregnancy require prompt contact with your OB-GYN or immediate emergency room evaluation: vaginal bleeding at any stage of pregnancy, particularly heavy bleeding or bleeding accompanied by cramping; severe or sudden abdominal pain or cramping that is not relieved with rest; signs of preterm labor before 37 weeks, including regular contractions (more than 4 per hour), pelvic pressure, low backache, or vaginal discharge changes; sudden severe headache that does not respond to acetaminophen, particularly when accompanied by visual changes such as blurring or flashing lights (these can be signs of preeclampsia); swelling of the face or hands that is sudden or severe (edema may indicate preeclampsia, a serious pregnancy complication affecting blood pressure); decreased or absent fetal movement in the second or third trimester: contact your provider if you notice a significant reduction in fetal movements over 2 hours of monitoring; leaking or gushing fluid from the vagina (which could indicate premature rupture of membranes); fever above 100.4°F (38°C), which may indicate infection; burning or pain with urination (urinary tract infections are common in pregnancy and require treatment to prevent progression to kidney infection); and signs of deep vein thrombosis (DVT) including unilateral leg pain, swelling, or redness, as pregnant women have significantly elevated DVT risk. Preeclampsia, in particular, is a leading cause of maternal and perinatal mortality in the United States, affecting 5 to 8% of pregnancies, and its symptoms (headache, visual changes, right upper quadrant pain, sudden facial swelling) require immediate evaluation. The ACOG preeclampsia resources at acog.org and the Preeclampsia Foundation at preeclampsia.org provide detailed information on recognizing and responding to this serious pregnancy complication.

EDD stands for Estimated Due Date, which is the term most commonly used in contemporary US obstetric practice to refer to the calculated date when the pregnancy is expected to reach 40 weeks gestation and spontaneous labor is anticipated. EDC stands for Estimated Date of Confinement, an older term from historical obstetric practice when “confinement” referred to the period when a woman was expected to remain at home (or in the hospital) around the time of delivery. EDC and EDD refer to the same date: both are calculated using Naegele’s Rule (LMP plus 280 days) or ultrasound dating and represent the 40-week gestational age endpoint of the pregnancy. The term EDC has fallen out of common use in patient communication in modern US practice (the concept of “confinement” no longer reflects how birth and postpartum care are understood), though you may still encounter it on older medical records, insurance documentation, or in academic obstetric literature. Some providers also use the term EDA (estimated date of arrival) in patient-friendly communication. Regardless of the abbreviation, the date represents the same calculation and carries the same clinical meaning: the date 280 days after the first day of the last menstrual period, or the equivalent date derived from first trimester ultrasound dating. For documentation purposes, the date calculated by this calculator can be described as the EDD, EDC, or estimated due date with equivalent clinical meaning. If you see EDC on your prenatal chart and are uncertain whether it matches your EDD as calculated here, confirm with your OB-GYN’s office that the two dates agree, as any discrepancy may indicate a dating adjustment made based on ultrasound findings that should be reflected in your personal tracking as well.